Observation of the Incretin Effect in Critically Ill patients by Jamaludin, U. et al.
ON/OFF 
 
Time* 
(hr) 
Blood Glucose (ΔBG) Insulin Sensitivity (ΔSI) 
Median IQR p-value Median IQR p-value SI (↑) 
-2 0% [0,0]% 1.0 0% [0,0] 1.0 50% 
-1 0% [-3,6]% 1.0 0% [-10,12]% 0.9 50% 
0 -1% [-9,5]% 0.7 -2% [-16,18]% 0.7 46% 
1 -2% [-12,8]% 0.6 -9% [-30,23]% 0.3 38% 
2 -1% [-12,9]% 0.6 -10% [-45,15]% 0.05 27% 
3 -4% [-15,10]% 0.5 -29% [-59,15]% 0.01 29% 
4 0% [-16,17]% 0.4 -36% [-82,24]% 0.001 37% 
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Objective 
The impact of endogenous insulin secretion and its interaction with 
feeding method (enteral - EN or parenteral – PN) in glycemic control 
protocols is unknown. This study examines whether there is any evidence 
for an EN – driven incretin effect. 
Method 
  
The incretin effect was observed via changes in a lumped insulin 
sensitivity parameter in 52 patients on SPRINT glycemic control. Patients 
with diabetes were excluded.  
Figure 1. A patient example of incretin effect analysis flow chart  
Conclusions 
A significant incretin effect was observable at a cohort level. The impact was 
stronger for the OFF/ON transition indicating that this effect was suppressed by 
long-term continuous EN infusions. These results provide the data to design 
conclusive studies, as well as to inform glycemic control protocol development. 
Results 
Figure 2. BG and SI changes at ON/OFF and OFF/ON EN transitions when t*=4  
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Time* (hr) 
Blood Glucose (ΔBG) Insulin Sensitivity (ΔSI) 
Median IQR p-value Median IQR p-value SI (↓) 
-2 0% [0 0]% 1.0 0% [0 0]% 1.0 50% 
-1 -1% [-6,2]% 0.6 4% [-13,12]% 0.9 39% 
0 -1% [-9,6]% 0.9 8% [-14,23]% 0.9 40% 
1 -3% [-11,7]% 0.6 14% [-5,29]% 0.5 33% 
2 -2% [-10,15]% 0.9 25% [-10,46]% 0.3 29% 
3 1% [-12,15]% 0.7 32% [-5,53]% 0.05 32% 
4 6% [-15,18]% 0.5 31% [-1,60]% 0.03 25% 
0 0.5 1 1.5 2
x 10-3
-200
-150
-100
-50
0
50
100
150
SI [L.mU
-1.min-1]
∆
 S
I 
(%
)
ON/OFF
 
 
75% prctile
25% prctile
median
95% prctile
5% prctile
Sepsis Traumatic Pancreatitis others
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
x 10-3
-200
-100
0
100
200
SI [L.mU
-1.min-1]
∆
 S
I 
(%
)
OFF/ON
 
 
75% prctile
25% prctile
median
95% prctile
5% prctile
Sepsis Traumatic Pancreatitis others
Key Outcomes  
The insulin sensitivity shifts at both feed transitions were consistent with an 
active incretin effect.  The SPRINT glycemic control protocol maintained stable 
glucose despite the altered patient physiology 
